ArticleNPJ precision oncology2026

Cetuximab plus capecitabine every three weeks as first-line maintenance therapy for RAS/BRAF wild-type metastatic colorectal cancer: a phase Ib dose-escalation study.

Xiaoyu Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.